Login to Your Account



DEALS AND M&A NEWS

DUBLIN – Curevac GmbH has found another taker for its mRNA-based vaccine technology, in the shape of Boehringer Ingelheim GmbH, which is paying €35 million (US$45.4 million) up front and up to €430 million in milestones for global development rights to CV9202, a therapeutic vaccine in development for non-small-cell lung cancer (NSCLC).

Auxilium Pharmaceuticals Inc.'s shares rose 44.8 percent to close at $31.17 Wednesday following Endo's unsolicited $2.2 billion bid for the company, a development that could throw a wrench in Auxilium's plans to merge with Canada's QLT Inc.

Following up last year's deal with Baxter International Inc. for the JAK inhibitor pacritinib in myelofibrosis, CTI Biopharma's sealed an agreement with Les Laboratoires Servier SA that brings €14 million up front and could be worth as much as €103 million if all milestones are achieved.

More DEALS AND M&A Headlines

Cast Your Vote

Has biotech’s bubble burst?: